Factors associated with response to apricitabine in a phase 2b study in treatment-experienced patients with HIV-1 infection
S. Cox*, J. Southby
Avexa Ltd, Melbourne, Australia
All abstracts are under embargo until the date and time of presentation at the conference.
19-22 July
http://www.ias2009.org/mainpage.aspx?pageId=334
